Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz

Antiviral Therapy

Volumn 6, Issue 4, 2001, Pages 249-253

  Maggiolo, Franco ^a   Migliorino, Marco ^a   Maserati, Renato ^a   Pan, Angelo ^a   Rizzi, Marco ^a   Pravettoni, Grazia ^a   Rizzi, Laura ^a   Suter, Fredy ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; VIRUS RNA;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; OXAZINES; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 0035715574     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice
2. Adverse effects of antiretroviral therapy
3. A risk-benefit assessment of HIV prorease inhibitors
4. Rethinking nonadherence: Historical perspectives on triple-drug therapy for HIV disease
5. Pharmacokinetics of efavirenz alone and in combination therapy with nelfinavir in HIV-1 infected patients
6. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine
7. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1
8. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
9. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel
10. New antiretroviral drugs in development
11. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in human immunodeficiency virus-infected patients
12. Once daily therapy with nevirapine, didanosine, lamivudine in a non adherent population
13. Nevirapine, efavirenz, didanosine: A very simple, safe and effective once-daily regimen
14. First evaluation of a once a day HAART regimen in treatment naive HIV-1 infected adults in Senegal (ANRS 12-04/IMEA 011 Study)
15. Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients
16. Equivalence of plasma and intracellular triphosphate lamivudine pharmacokinetics following lamivudine 300 mg once daily compared to lamivudine 150 mg twice a day in healthy volunteers
17. Efficacy and safety of switch to 3TC 300 mg QD vs. continued 3TC 150 mg BID in subjects with virologic suppression on stable 3TC/d4T/PI therapy (COLA4005): Final 24-week results
18. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
19. Use of trizivir to simplify therapy in HAART-experienced subjects with long term suppression of HIV-RNA: TRIZAL study 24-week results
20. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV infected patients. The INCAS trial
21. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
22. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)
23. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population
24. Adherence and antiretroviral therapy in injection drug users
25. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
26. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load